About the study
PERFORM is a real-world (pragmatic) Phase 4 study comparing a once-daily triple-therapy inhaler, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), with the usual-care inhaled steroid and long-acting bronchodilator (ICS/LABA) inhalers in adults whose asthma is not well controlled. Participants are followed for 52 weeks, with the main analysis at 24 weeks.
Who took part
The study enrolled people who:
- Were 18 to 75 years old
- Had asthma that was not well controlled, either untreated or on a daily ICS or ICS/LABA inhaler
Status at Veritas
This study is active but no longer enrolling new participants. People already enrolled continue their study visits.
Learn more
The full study record, including all eligibility criteria and outcome measures, is on ClinicalTrials.gov (NCT06372496).